Dr. Disis is a Professor of Medicine and Adjunct Professor of Pathology and Obstetrics and Gynecology at the University of Washington (UW), and a Member of the Fred Hutchinson Cancer Research Center (FHCRC). She is the Associate Dean for Translational Science in the UW School of Medicine. Dr. Disis received her M.D. from the University of Nebraska Medical School and completed a residency and chief residency in Internal Medicine at the University of Illinois in Chicago. Her fellowship in oncology was completed at UW/FHCRC. Dr. Disis is an expert in breast and ovarian cancer immunology and translational research. She is one of the pioneering investigators who discovered that HER-2/neu is a tumor antigen. Her work has led to several clinical trials which evaluate boosting immunity to HER-2/neu with cancer vaccines. Dr. Disis is a member of Alpha Omega Alpha and the American Society of Clinical Investigation. She is the Editor in Chief for JAMA Oncology, and is a member of several committees and task forces for both the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR). She is also the Director of the Institute of Translational Health Sciences and the Director for the Cancer Vaccine Institute at the UW. Her multifaceted research program within the Cancer Vaccine Institute includes the discovery of new antigens for common solid tumors, the development of vaccine and cellular therapy targeting specific antigens, and immunodiagnostics.
Disis, Mary L. (Nora)
Associate Dean, Translational Science at the University of Washington (UW); Professor of Medicine and Adjunct Professor of Pathology and Obstetrics and Gynecology at UW; Athena Distinguished Professor of Breast Cancer Research